OncologyCE
EXPERT VIDEOCMECPE

Oncology Consults: The Latest on the Biosimilar Revolution

Author(s)/Faculty: Sanjiv S. Agarwala, MD; Ali McBride, PharmD, MS, BCOP, FASHP, FAzPA
Release Date: 6/28/2019Expiration Date: 6/27/2020
Credit Type: CME / CPENumber of Credits: 0.75
Content Type: VideoProvider:
Several of the most-used cancer drugs are biologics and many, including rituximab, bevacizumab, and trastuzumab, have biosimilars available and others that are currently in late-stage clinical development. In the United States, biosimilars have been approved for use since September 2015, yet oncologists, oncology nurses, and pharmacists lack knowledge regarding the differences between biosimilars and their reference products, as well as the clinical implications of biosimilars. Moreover, considering these knowledge gaps, providers are ill-equipped to discuss biosimilars with their patients, which negatively impacts shared decision-making and patient-centered care. This continuing medical education activity, led by expert clinicians, will educate oncology health care professionals about the latest advances regarding the use of biosimilars and how they can be applied in oncology practice.